Adagio Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adagio Therapeutics, Inc. (Nasdaq: ADGI) announced its participation in several upcoming investor conferences. Management will engage in fireside chat discussions at the Stifel 2021 Virtual Healthcare Conference on November 16, and at the Jefferies 2021 Virtual London Healthcare Conference from November 16-19. Also, a fireside chat is scheduled for the Evercore ISI 4th Annual HealthconX Conference on December 1, 2021. Webcasts will be available on the company's investor website for 60 days post-presentation. Adagio focuses on developing antibody-based solutions for infectious diseases, including COVID-19.

WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences:

• Stifel 2021 Virtual Healthcare Conference: Management will participate in a fireside chat discussion on Tuesday, November 16, 2021, at 8:40 a.m. ET.
  
• Jefferies 2021 Virtual London Healthcare Conference: Management will participate in a fireside chat discussion during the conference, being held November 16-19, 2021. The fireside chat will be available to registered participants on-demand between 8:00 a.m. GMT on November 18, 2021, and 5:00 p.m. GMT on November 19, 2021.
  
• Evercore ISI 4th Annual HealthconX Conference: Management will participate in a fireside chat discussion on Wednesday, December 1, 2021, at 2:40 p.m. ET.
  

The webcasts will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

FAQ

When is Adagio Therapeutics participating in the Stifel 2021 Virtual Healthcare Conference?

Adagio Therapeutics will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 8:40 a.m. ET.

What are the dates for the Jefferies 2021 Virtual London Healthcare Conference?

The Jefferies 2021 Virtual London Healthcare Conference is scheduled from November 16 to November 19, 2021.

When will Adagio participate in the Evercore ISI 4th Annual HealthconX Conference?

Adagio will participate in the Evercore ISI 4th Annual HealthconX Conference on December 1, 2021, at 2:40 p.m. ET.

How long will the webcasts of the investor conferences be available?

The webcasts will be available for 60 days following the presentations on Adagio's investor website.

What is the focus of Adagio Therapeutics?

Adagio Therapeutics focuses on the discovery and development of antibody-based solutions for infectious diseases, including COVID-19.